NALT 350 mg by Pure Nootropics — Ingredients, Evidence & Safety

🟢 100/100

This product looks safe

No ingredients exceed tolerable upper intake levels
100% of ingredients have research evidence

A Label Compliance Grade

Product Label

📄 Open Full PDF View on NIH DSLD →

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Capsule(s) Serving Size

120 Servings

Non-Nutrient/Non-Botanical Product Type

100% Evidence Coverage

Supplement Facts — Evidence Check

N-Acetyl L-Tyrosine

350 mg

📊 Market median: 500.0mg (223 products) 📚 22 studies (Tier A: 0, B: 1)

This product: 350mg

Other Ingredients

Hypromellose Maltodextrin

Label Claims — Verification

❓ All Other

❓ Structure/Function

All Other (98% of products) Structure/Function (78% of products) Nutrient (56% of products)

Target Groups

Adult (18 - 50 Years) Women (not pregnant or lactating) Gluten Free

Product Information

📋 Directions for Use

Suggested Use: Take 1 capsule daily or as recommended by your healthcare practitioner.

⚠️ Warnings & Precautions

Warning: Consult with a healthcare practitioner before taking this. If you experience adverse reactions from taking this product, discontinue immediately and contact a healthcare practitioner.

Do not take this if you are pregnant, nursing, or under the age of 18.

Keep out of the reach of children.

🧪 Formulation Notes

Zero GMO Gluten Preservatives

N-Acetyl-L-Tyrosine 350mg Per serving

Supports Healthy stress response and cognitive health

Additional Information

Purity Potency Safety 3rd Party Tested Guarantee Packaged in the USA Bottled in FDA registered Facilities

Unlock your potential

Product Details

UPC / SKU 854051008498

DSLD Entry Date 2024-08-22

Product Type Non-Nutrient/Non-Botanical

Form Capsule

Brand Pure Nootropics

DSLD ID 316594

Data Updated 2026-04-11

Research Evidence

50 Research Sources

47 Avg Quality Score

28 Rct

13 Clinical Trial

5 Guideline

4 Systematic Review

A Using a Novel Consensus-Based Chemoinformatics Approach to Predict ADMET Properties and Druglikeness of Tyrosine Kinase Inhibitors.

Guideline International journal of molecular sciences 2025

PubMed DOI

B Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors.

Guideline Internal medicine journal 2025

PubMed DOI

B Branched-chain amino acid supplementation for improving growth and development in term and preterm neonates

Systematic Review The Cochrane database of systematic reviews 2020

PubMed DOI Cochrane

B [Clinical practice guideline on anaplastic lymphoma kinase-tyrosine kinase inhibitors for non-small cell lung cancer (2025 edition)].

Guideline Zhonghua zhong liu za zhi [Chinese journal of oncology] 2025

PubMed DOI

B [Chinese expert consensus on epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer (2025 edition)].

Guideline Zhonghua yi xue za zhi 2025

PubMed DOI

B Consensus Guideline for the Diagnosis and Treatment of Tyrosine Hydroxylase (TH) Deficiency.

Guideline Journal of inherited metabolic disease 2025

PubMed DOI

B Baseline-dependent effect of dopamine's precursor L-tyrosine on working memory gating but not updating

Rct Cognitive, affective & behavioral neuroscience 2020

PubMed DOI

B Effect of Amino Acid Supplementation on Iron Regulation after Endurance Exercise

Rct Nutrients 2023

PubMed DOI

C Attenuating Muscle Damage Biomarkers and Muscle Soreness After an Exercise-Induced Muscle Damage with Branched-Chain Amino Acid (BCAA) Supplementation: A Systematic Review and Meta-analysis with Meta-regression

Systematic Review Sports medicine - open 2024

PubMed DOI

C The Effects of Green Tea Amino Acid L-Theanine Consumption on the Ability to Manage Stress and Anxiety Levels: a Systematic Review

Systematic Review Plant foods for human nutrition (Dordrecht, Netherlands) 2020

PubMed DOI

View all evidence for Tyrosine →